260.a ABO-incompatible Living Kidney Transplantation
Kazunari Tanabe, Japan
260.1 Increased risk of acute antibody-mediated rejection despite long-term compromised B cell repopulation after rituximab induction in blood group incompatible living-donor renal transplantation
Prof. Rolf Weimer, Germany
260.2 Deceased-donor acute kidney injury: Impact on postransplant outcome
Dr. Maribel Merino-López, Mexico
260.4 Cellular responses of donor kidneys during normothermic machine perfusion predict post-transplant outcome
Miss Shengbing Li, Netherlands
260.5 Current status of ABO incompatible kidney transplantation in Japan ― based on statistical data of renal transplantation in Japan
Prof. Yuki Nakagawa, Japan
260.6 A single centre ABO incompatible transplantation experience of 160 patients in North India : Outcomes, protocols and the way forward
Dr. Aviral Kashyap, India
260.7 Comparison of thymoglobulin and grafalon as induction agents in ABO- incompatible kidney transplantation – A single centre retrospective study
Dr. Deepak Shankar Ray, India
260.8 A retrospective cohort study of ABO-incompatible living kidney donor transplantation before and during the COVID-19 Pandemic
Mr. Darren Lim Zi Yang, Singapore
260.9 Crossmatch-Positive, Highly Sensitized Kidney Transplant Recipients after Desensitization with Rituximab ± Bortezomib
Dr. Kentaro Ide, Japan
260.10 Playing hide and seek with HLA-DRB3/4/5 data in kidney transplantation reports in Argentina
Manuel E. Quirno Costa, Argentina
260.11 Impact of HLA Donor Specific Antibody Vs Non-Donor Specific Antibodies by Single Antigen Bead method in predicting Outcome of Living related renal allograft recipients